Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03583138 · ClinicalTrials.gov registry record
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
A clinical trial of Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome, sponsored by Yale University.
- Completed
- Registry status
- 159
- Enrollment target
- 1
- Study location
NCT03583138 is a study of Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome that has completed, run by Yale University. The registered enrollment target is 159 participants, below the 180-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03583138, a study of Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
- 1
- Study location
Study Summary
STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.
Conditions Studied
Interventions
- DRUG buprenorphine
Study Locations (1)
District of Columbia
- Howard University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2014-06-23 |
| Est. Completion | 2017-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03583138
The ClinicalTrials.gov registry entry for NCT03583138 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (12% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which buprenorphine is the first listed.
NCT03583138 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03583138 about?
NCT03583138 is a clinical study titled "HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)". STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard...
What is the current status of trial NCT03583138?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2014-06-23. Estimated completion is 2017-06-30.
What conditions does trial NCT03583138 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Drug Dependence, Opiate Addiction.
What interventions are being tested in trial NCT03583138?
The interventions under investigation include: buprenorphine (DRUG).
Who is sponsoring clinical trial NCT03583138?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03583138 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
Baricitinib for Reduction of HIV - CNS
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
RECRUITING
-
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
RECRUITING
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
Explore more on PlainTrial
Human Immunodeficiency Virus
All registered trials for this condition
Acquired Immunodeficiency Syndrome
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.